Physician profile
Syed Mustafa
NPI 1326393885
$5,064.72
in general payments reported to CMS, 2019-2025
33 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 79% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $77.33 · 2021: $520 · 2022: $320 · 2023: $709 · 2024: $1,657 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,248.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $500.48 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Olympus Corporation of The Americas | $447.08 | 2019 | |
| Shockwave Medical, INC | $270.41 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $247.97 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Actelion Pharmaceuticals US, INC. | $238.30 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.76 | 2019-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| United Therapeutics Corporation | $191.53 | 2019-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $187.70 | 2024-2025 | Verquvo, Zerbaxa |
| Abiomed | $156.23 | 2021-2025 | |
| Penumbra, INC. | $141.22 | 2024 | Indigo System |
| Electromed, INC. | $128.43 | 2021-2025 | Smartvest |
| Genzyme Corporation | $104.40 | 2023-2024 | |
| Amgen INC. | $100.07 | 2023-2024 | Tezspire, Tavneos |
| Mallinckrodt Hospital Products INC. | $99.20 | 2023-2024 | Acthar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Mylan Specialty L.P. | $75.84 | 2023-2024 | Yupelri |
| Insmed, INC. | $70.04 | 2024-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $68.70 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $60.28 | 2019-2021 | |
| Grifols USA, LLC | $59.62 | 2023-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $58.87 | 2021-2025 | Glassia |
| Medtronic, INC. | $51.49 | 2025 | Illumisite |
| Scpharmaceuticals INC. | $46.80 | 2025 | |
| Philips North America LLC | $34.87 | 2021-2024 | (Ak6) Vest Therapy |
| Allergan, INC. | $33.48 | 2019 | |
| Baxter Healthcare | $24.23 | 2024 | Hillrom - Life 2000 Ventilation System |
| Heartflow, INC. | $23.17 | 2023 | Ffrct |
| Ethicon INC. | $18.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.15 | 2025 | |
| Verona Pharma, INC. | $17.74 | 2025 | Ohtuvayre |
| Coaptech, INC. | $17.12 | 2024 | Puma System |
| Olympus America INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.